385 related articles for article (PubMed ID: 30202791)
1. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
Touyz RM; Herrmann J
NPJ Precis Oncol; 2018; 2():13. PubMed ID: 30202791
[TBL] [Abstract][Full Text] [Related]
2. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
Groarke JD; Choueiri TK; Slosky D; Cheng S; Moslehi J
Curr Treat Options Cardiovasc Med; 2014 Sep; 16(9):335. PubMed ID: 25099086
[TBL] [Abstract][Full Text] [Related]
3. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events.
Touyz RM; Herrmann SMS; Herrmann J
J Am Soc Hypertens; 2018 Jun; 12(6):409-425. PubMed ID: 29703600
[TBL] [Abstract][Full Text] [Related]
4. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
5. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers.
Nhola LF; Abdelmoneim SS; Villarraga HR; Kohli M; Grothey A; Bordun KA; Cheung M; Best R; Cheung D; Huang R; Barros-Gomes S; Pitz M; Singal PK; Jassal DS; Mulvagh SL
J Am Soc Echocardiogr; 2019 Feb; 32(2):267-276. PubMed ID: 30459123
[TBL] [Abstract][Full Text] [Related]
6. Hypertension in cancer patients treated with anti-angiogenic based regimens.
Wasserstrum Y; Kornowski R; Raanani P; Leader A; Pasvolsky O; Iakobishvili Z
Cardiooncology; 2015 Dec; 1(1):6. PubMed ID: 33530150
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib-associated multivessel coronary artery vasospasm.
Naib T; Steingart RM; Chen CL
Herz; 2011 Jun; 36(4):348-51. PubMed ID: 21584715
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma.
Franczyk B; Rysz J; Ławiński J; Ciałkowska-Rysz A; Gluba-Brzózka A
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672689
[TBL] [Abstract][Full Text] [Related]
11. Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.
Kim JY; Hwang J; Lee SH; Lee HJ; Jelinek J; Jeong H; Lim JS; Kim JM; Song KS; Kim BH; Lee S; Kim J
Clin Epigenetics; 2015; 7():99. PubMed ID: 26380584
[TBL] [Abstract][Full Text] [Related]
12. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.
Wu Q; Bai B; Tian C; Li D; Yu H; Song B; Li B; Chu X
Cardiovasc Drugs Ther; 2022 Jun; 36(3):511-524. PubMed ID: 33847848
[TBL] [Abstract][Full Text] [Related]
13. Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy.
Moriyama S; Hieda M; Kisanuki M; Kawano S; Yokoyama T; Fukata M; Kusaba H; Maruyama T; Baba E; Akashi K; Fukuda H
Circ J; 2024 Jan; 88(2):217-225. PubMed ID: 36476830
[TBL] [Abstract][Full Text] [Related]
14. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Maitland ML; Bakris GL; Black HR; Chen HX; Durand JB; Elliott WJ; Ivy SP; Leier CV; Lindenfeld J; Liu G; Remick SC; Steingart R; Tang WH;
J Natl Cancer Inst; 2010 May; 102(9):596-604. PubMed ID: 20351338
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
17. Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
Mozolevska V; Schwartz A; Cheung D; Goyal V; Shaikh B; Dingman B; Kim E; Mittal I; Asselin CY; Edel A; Ravandi A; Thliveris J; Singal PK; Czaykowski P; Jassal DS
Am J Physiol Heart Circ Physiol; 2019 Mar; 316(3):H446-H458. PubMed ID: 30499710
[TBL] [Abstract][Full Text] [Related]
18. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.
Stuhlmiller TJ; Zawistowski JS; Chen X; Sciaky N; Angus SP; Hicks ST; Parry TL; Huang W; Beak JY; Willis MS; Johnson GL; Jensen BC
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29051215
[TBL] [Abstract][Full Text] [Related]
19. The role of antiangiogenetic agents in the treatment of breast cancer.
Bareschino MA; Schettino C; Colantuoni G; Rossi E; Rossi A; Maione P; Ciardiello F; Gridelli C
Curr Med Chem; 2011; 18(33):5022-32. PubMed ID: 22050750
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
Park K; Lee JL; Park I; Park S; Ahn Y; Ahn JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Med Oncol; 2012 Dec; 29(5):3291-7. PubMed ID: 22460837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
